Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 52-Week High at $17.54

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as $17.54 and last traded at $17.51, with a volume of 6441192 shares traded. The stock had previously closed at $16.85.

Wall Street Analyst Weigh In

A number of analysts have recently commented on TEVA shares. Piper Sandler reissued an “overweight” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 5th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 20th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a research report on Friday, March 8th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.88.

Teva Pharmaceutical Industries Stock Up 3.1 %

The stock has a market capitalization of $19.48 billion, a price-to-earnings ratio of -41.63, a price-to-earnings-growth ratio of 1.61 and a beta of 0.91. The stock has a 50 day moving average price of $15.08 and a 200 day moving average price of $13.02. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The company had revenue of $3.82 billion for the quarter, compared to the consensus estimate of $3.70 billion. Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. As a group, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.3 EPS for the current year.

Insider Activity

In related news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction on Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Amir Weiss sold 15,500 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total transaction of $260,400.00. Following the sale, the chief accounting officer now owns 17,814 shares in the company, valued at approximately $299,275.20. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Edmond DE Rothschild Holding S.A. lifted its holdings in Teva Pharmaceutical Industries by 4.0% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock valued at $346,000 after acquiring an additional 947 shares during the period. Desjardins Global Asset Management Inc. grew its position in Teva Pharmaceutical Industries by 15.2% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock valued at $85,000 after buying an additional 1,070 shares during the period. Oppenheimer & Co. Inc. increased its holdings in Teva Pharmaceutical Industries by 9.6% during the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after buying an additional 1,180 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 67,996 shares of the company’s stock worth $688,000 after acquiring an additional 1,375 shares during the period. Finally, ClariVest Asset Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 0.4% during the 3rd quarter. ClariVest Asset Management LLC now owns 399,900 shares of the company’s stock worth $4,079,000 after acquiring an additional 1,400 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.